Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 3 sources · 23 days · First seen 26 days ago · Last updated 3 days ago

Sandoz biosimilar business expansion

Overview

Sandoz is expanding its biosimilar business through strategic partnerships and infrastructure investment. In August 2026, the company entered a $322 million collaboration with Shanghai Henlius Biotech to develop and commercialize up to ten biosimilar products outside of China, focusing initially on treatments for colorectal cancer, hypercholesterolemia, and lupus.

Following this, in September 2026, Sandoz announced a $300 million investment to establish a new biosimilar drug substance facility in Ljubljana, Slovenia. The facility, intended to be operational by 2029, aims to increase the company’s European manufacturing capacity and support its ‘Bio100’ goal of expanding its market share in affordable medicines.

Entities

Sandoz · Ljubljana · Amgen · Bristol-Myers Squibb · Shanghai Henlius Biotech

Timeline

3 days ago

[BUSINESS] 3 sources
Sandoz to invest USD 300 million in Slovenian biosimilar facility
Sandoz is investing USD 300 million to build a new biosimilar drug substance facility in Ljubljana, Slovenia, adding 8,000 litres of capacity by 2029.
26 days ago

[BUSINESS] 12 sources
Sandoz and Henlius Biotech sign $322 million biosimilar deal
Sandoz and Shanghai Henlius Biotech have signed a strategic deal worth up to $322 million to develop and commercialize up to 10 biosimilars globally, targeting cancer, lupus, and cholesterol treatments.

Sources

biotech-investments.com · drug-dev.com · news.cube-soft.jp